As of Wednesday close, AstraZeneca PLC’s (NASDAQ:AZN) stock was up $0.12, moving up 0.18 percent to $66.12. The average number of shares traded per day over the past five days has been 4,781,340 shares. 5 times new highs have been achieved over the past 5 days, with a $2.32 gain in that time frame. In the last twenty days, the average volume was 5,626,865, while in the previous 50 days, it was 6,329,782.
Since last month, AZN stock rose 18.28%. Shares of the company fell to $55.00 on 10/24/22, the lowest level in the past month. A 52-week high of $71.70 was reached on 04/08/22 after having rallying from a 52-week low of $52.65. Since the beginning of this year, AZN’s stock price has risen by 13.51% or $7.87, and marked a new high 20 times. However, the stock has declined by -7.78% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
Right now, AstraZeneca PLC (AZN) has a P/E ratio of about 101.26. The stock’s beta is 0.52. Besides these, the trailing price-to-sales (P/S) ratio of 4.49, the price-to-book (PB) ratio of 5.83, and the price-to-cash flow ratio of 59.25 may also be considered.
The latest dividend of $0.4650 per share was paid out, which is -52.79% less than last year’s $0.9850. On Monday August 1 2022, a $0.52 dividend decrease was announced.
In the three months ended June 29, AstraZeneca PLC’s quick ratio stood at 0.60, while its current ratio was 0.80, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.67, and the total debt-to-equity ratio was 0.83. On the profitability front, the trailing twelve-month gross margin is 79.20% percent. In the year ended June 29, EBITDA margin amounted to 18.41%, whereas operating margins totaled 5.20%. Based on annual data, AZN earned $24.98 billion in gross profit and brought in $37.42 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 2.00%. Return on equity (ROE) for the past 12 months was 5.60%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. AZN’s revenue rose 28.86% during the quarter, while net income inched up to $37.42 billion. While analysts expected AstraZeneca PLC to report $0.77 quarterly earnings, the actual figure was $0.86 per share, beating the consensus estimate by 11.70%. During the quarter, the company generated $2.58 billion in EBITDA. The liabilities of AstraZeneca PLC were 59.03 billion at the end of its most recent quarter ended June 29, and its total debt was $31.39 billion.
This quick technical analysis looks at AstraZeneca PLC’s (AZN) price momentum. With a historical volatility rate of 23.56%, the RSI 9-day stood at 77.86% on 23 November.
With respect to its five-day moving average, the current AstraZeneca PLC price is up by +3.64% percent or $2.32. At present, AZN shares trade +14.08% above its 20-day simple moving average and +0.93% percent above its 100-day simple moving average. However, the stock is currently trading approximately +12.60% above its SMA50 and +16.72% above its SMA200.
Stochastic coefficient K was 95.63% and Stochastic coefficient D was 91.46%, while ATR was 1.29. Given the Stochastic reading of 95.07% for the 14-day period, the RSI (14) reading has been calculated as 73.14%. As of today, the MACD Oscillator reading stands at 1.28, while the 14-day reading stands at 2.23.
AstraZeneca PLC downgraded its rating on AstraZeneca PLC (NASDAQ: AZN) to a Neutral in a note to investors on September 15, 2022. The analysts firm previously had an Outperform rating on the stock.AstraZeneca PLC (AZN) has been rated Buy by analysts. According to 0 brokerage firms, AZN is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 3 analysts rate AstraZeneca PLC stock as buy, with 21 recommending it as overweight.